Pds Biotechnology Corporation · NASDAQ:PDSB
Pds Biotechnology — Investor Presentation (March 2024)
17 slides from Pds Biotechnology's investor presentation, Mar 27, 2024
Slide 1: Transforming How the Immune System Targets and Fights Cancer
Transforming How the Immune System Targets and Fights Cancer NASDAQ: PDSB March 2024
Slide 2: Forward-Looking Statement
Forward-Looking Statement This communication contains forward-looking statements (including within the meaning of Section 27E of the United States Securities Exchange Act of 7934, as amended, and Section 27A of the United States Securities Act of 7933, as amended) concerning PDS Biotechnology Corpor
Slide 3: Late-Stage Head and Neck Cancer Program as Value Catalyst
Late-Stage Head and Neck Cancer Program as Value Catalyst Pivotal trial planned for PDS01ADC + Versamune® HPV (PDS0101) + KEYTRUDA® in head and neck cancer High-Value Lead Program PDS01ADC + Versamune® disrupts tumor’s inside defenses, and generates potent, targeted killer T-cell attack from outside
Slide 4: Strategy Addresses Why Immunotherapies Fail in Solid Tumors
Strategy Addresses Why Immunotherapies Fail in Solid Tumors References: Darvin et al. Immune Checkpoint Inhibitors, Recent Progress and Potential Biomarkers; Experimental & Molecular Medicine (2018) 50:165. Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer–immune set point. Nature
Slide 5: Combination Platform Enables Inside-Outside Attack to Address Limits
Infiltrates TME to Suppress the Tumor’s Defenses & Promotes T Cell Infiltration/Immunogenicity Combination Platform Enables Inside-Outside Attack to Address Limits Immuno-cytokine IL-12 Fused Antibody Drug Conjugate PDS01ADC First immuno-cytokine antibody drug conjugate NHS76 (Tumor Necrosis Targeti
Slide 6: PDS01ADC + Versamune + ICI: Unique Combined Mechanism
PDS01ADC + Versamune® + ICI: Unique Combined Mechanism Mechanism Attacks the Tumor from Both the Inside (TME) and Outside of the Tumor Inside 1 PDS01ADC Infiltrates TME; Weakens Tumor’s Protection from Immune System StimulatesT Cells in TME to Promote Expansion + Prolonged, Effective Killing Versamu
Slide 7: PDS01ADC and Versamune Have Broad Therapeutic Potential
PDS01ADC and Versamune® Have Broad Therapeutic Potential Synergistic Effect With SoC Modalities Across a Spectrum of Tumors PDS01ADC Versamune® Conjugate limits systemic toxicity of IL-12 Activates/expands T cells in tumor & limits T cell exhaustion Changes tumor to become more permissive to T cell
Slide 8: Patients Had Sustained Tumor Shrinkage, Objective Response Rate
Patients Had Sustained Tumor Shrinkage, Objective Response Rate ICI Resistant Cancer 1. Burtness B et al., Lancet. 2019; 394:1915-1928. 2. Triple combination Phase 2 trial (NCT04287868, Investigator assessment (11/2023) 1. Strauss J et al, Journal for ImmunoTherapy of Cancer 2020;8:e001395. 2. INTER
Slide 9: Triple Combination Has Shown Compelling Survival Data
Triple Combination Has Shown Compelling Survival Data Proof-of-Concept in ICI-resistant Cancer Validates MOA and Preclinical Results One-Year Survival Median Overall Survival 1. Strauss J et al, Journal for ImmunoTherapy of Cancer 2020;8:e001395. 2. Pestana, et al. Oral Oncology. 2022:104523. 3. Tri
Slide 10: Compelling Long-Term Survival of ICI Naïve Advanced HNSCC Patients
Compelling Long-Term Survival of ICI Naïve Advanced HNSCC Cancer Patients (Double & Triple Combinations) PDS01ADC and Versamune® HPV May Significantly Promote Patient Survival (N=53 HNSCC Patients) (HNSCC Patients) (HNSCC Patients) (N=29 Anal, cervical, HNSCC, Vaginal, Vulvar Patients) 1. Burtness B
Slide 11: Proof-of-Concept Results Indicate Favorable Tolerability
Proof-of-Concept Results Indicate Favorable Tolerability 48% Had Grade 3 TRAEs, 4% Grade 4 Safety Population: All enrolled subjects who received at least 1 dose of any drug National Cancer Institute. (2023). Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies. [Data set]
Slide 12: Program Is Supported and Validated by Robust Clinical Data
Program Is Supported and Validated by Robust Clinical Data Experience in More Than 430 Patients PDS01ADC + Versamune® HPV + Bintrafusp alfa (triple) and Versamune® HPV + KEYTRUDA® (double) administered to 110+ head & neck cancer patients to date HNSCC Patient Exposure Across Product Portfolio Well-t
Slide 13: HNSCC: Devastating Cancers with High Prevalence and Mortality
HNSCC: Devastating Cancers with High Prevalence and Mortality References: Johnson, D.E., Burtness, B., Leemans, C.R.et al.Head and neck squamous cell carcinoma.Nat Rev Dis Primers6, 92 (2020) Noseyaba et al. 2018. Cancer. Suicide Risk Among Cancer Survivors: Head and Neck Versus Other Cancers https:
Slide 14: HPV16-positive HNSCC Presents Significant Initial Market Opportunity
Est. HPV16Locally Advanced,Unresectable andMetastatic HNSCC HPV16-positive HNSCC Presents Significant Initial Market Opportunity Epidemiology-Based Estimate of Addressable Population: HNSCC Company market research ~13,600 ~18,200 ~22,000 ~53,305 Est. U.S. HPV Positive HNSCC Est. U.S. HNSCC Est. HPV1
Slide 15: Pipeline Continues to Validate Platforms, Drive Future Opportunities
Candidate/ Study Indication PC P1 P2 P3 Partner PDS01ADC + Versamune® HPV + ICI Recurrent or metastatic HPV16-positive HNSCC PDS01ADC + Versamune® MUC1 + ICI (Phase 1/2 anticipated 2024) Recurrent or metastatic colorectal cancer Versamune® HPV + ICI (KEYTRUDA) Recurrent or metastatic HPV16-positive
Slide 16: Veteran New Leadership to Execute Strategy
Veteran New Leadership to Execute Strategy Record of Execution in Development, Commercialization of Leading Pharmaceutical Products Frank Bedu-Addo, PhD Chief Executive Officer Senior executive experience with management of strategy and execution at both large pharma and biotechs Notable drug develo
Slide 17: Thank You
Thank You Of} te: By NASDAQ: PDSB
PDS Biotechnology — Investor Presentation (March 2024) on 6ix